Adoption of promising technologies continues to stall in the biopharmaceutical industry. Participants in a roundtable discussion at the BioInnovation Group’s 2025 Executive Summit explored how new supported-funding approaches can derisk and accelerate early stage innovations.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.